Latest Stock/Share Market Updates | Corporate News | Announcements | BSE
Notices Media Release Trading Holidays BSEPlus Contact Us
हिन्दी     मराठी     ગુજરાતી


Latest Corporate Announcements

Announcement Type :   Search By :    
Security Name
Category
Date Calendar
To Date Calendar
Disclaimer  Next >>
   
Security Code : 532488    Company : DIVI'S LABORATORIES LTD.
22 Aug 2017
Fixes Book Closure for Dividend & AGMAGM/EGMDownload PDF
  Exchange Disseminated Time     22/08/2017 12:39:50
Divis Laboratories Ltd has informed BSE that the Register of Members & Share Transfer Books of the Company will remain closed from September 19, 2017 to September 25, 2017 (both days inclusive) for the purpose of Payment of Dividend & 27th Annual General Meeting (AGM) of the Company to be held on September 25, 2017.

The dividend, if declared at the Annual General Meeting, will be credited / dispatched on or before October 10, 2017.
 
21 Aug 2017
  Fixes Book Closure For Annual General Meeting And DividendCorp. ActionDownload PDF
  Exchange Received Time  21/08/2017 11:26:08         Exchange Disseminated Time   21/08/2017 11:26:15              Time Taken   00:00:07
We hereby inform you that 27th Annual General Meeting (AGM) of the members of the company will be held on Monday, the 25th day of September 2017 at 10.00 A.M. at Global Peace Auditorium, Brahma Kumaris, Shanti Sarovar, Academy for Better World, Gachibowli, Hyderabad – 500 032.

The Register of Members and Share Transfer Books of the Company will remain closed from Tuesday, September 19, 2017 to Monday, September 25, 2017 (both days inclusive) ....
04 Aug 2017
UpdatesCompany UpdateDownload PDF
  Exchange Received Time  04/08/2017 14:37:19         Exchange Disseminated Time   04/08/2017 14:37:25              Time Taken   00:00:06
Divi's Laboratories Limited, Unit-2 Vishakhapatnam has been inspected by 5 inspectors from HPRA (Ireland) and JAZMP (Slovenia) from 31st July 2017 to 4th August 2017.

The inspection was focused on:

1)Follow up on the effectiveness of the CAPA's implemented from the last JAZMP inspection
2)General GMP inspection of the site
The inspection has concluded successfully with no critical observations.

 
22 Jul 2017
Outcome of Board MeetingBoard MeetingDownload PDF
  Exchange Received Time  22/07/2017 15:28:50         Exchange Disseminated Time   22/07/2017 15:28:54              Time Taken   00:00:04
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors at its meeting held on 22nd July, 2017 has appointed Dr. S. Ganapaty as an Additional (Independent) Director w.e.f. 22nd July, 2017.
 
  Un-Audited Financial Results For The Quarter Ended 30.06.2017ResultDownload PDF
  Exchange Received Time  22/07/2017 13:49:51         Exchange Disseminated Time   22/07/2017 13:50:00              Time Taken   00:00:09
Further to our letter dated 14th July, 2017, we would like to inform that the Board of Directors of the Company at its meeting held on Saturday, 22nd July 2017 has approved Un-audited Financial Results for the first quarter ended 30th June, 2017.

In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we are enclosing herewith the following: ....
17 Jul 2017
Shareholding for the Period Ended June 30, 2017Company Update 
  Exchange Disseminated Time     17/07/2017 12:26:10
Divis Laboratories Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2017. For more details, kindly Click here
 
14 Jul 2017
   Meeting Of Board Of Directors Of The Company To Be Held On Saturday, The 22Nd Day Of July 2017Board MeetingDownload PDF
  Exchange Received Time  14/07/2017 13:16:25         Exchange Disseminated Time   14/07/2017 13:16:31              Time Taken   00:00:06
Notice is hereby given that a meeting of Board of Directors of the Company is scheduled to be held on Saturday, the 22nd day of July 2017, inter-alia, to consider and approve un-audited financial results for the quarter ended 30th June 2017.

We further inform you that the Trading Window for dealing in securities of the Company shall remain closed for insiders of the company from 15th July, 2017 to 24th July, 2017 (both days inclusive) ....
13 Jul 2017
  Statement Showing The Investor Complaints For The Quarter Ended 30Th June, 2017Company UpdateDownload PDF
  Exchange Received Time  13/07/2017 14:04:57         Exchange Disseminated Time   13/07/2017 14:05:01              Time Taken   00:00:04
In compliance with Regulation 13(3) of SEBI (LODR) Regulations, 2015, please find below the statement of investors complaints for the quarter ended 30th June, 2017:

SI.No. Particulars Number
1 Number of complaints pending at the beginning of the quarter Nil
2 Number of complaints received during the quarter 1 ....
11 Jul 2017
  UpdatesCompany UpdateDownload PDF
  Exchange Received Time  11/07/2017 14:13:56         Exchange Disseminated Time   11/07/2017 14:14:03              Time Taken   00:00:07
Sub: Discrepancies in Financial Result of the Company for the Quarter /Year ended March 2017

Ref : 1. SEBI circular ref No. CIR/CFD/FAC/62/2016 dated July 05, 2016
2. Your email dated 10th July, 2017


With reference to the above, please find attached herewith the declaration/undertaking on the audited standalone and consolidated financial results of the Company duly signed for the year ended 31st March 2017. ....
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011Insider Trading / SASTDownload PDF
  Exchange Disseminated Time     11/07/2017 10:37:37
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers)Regulations, 2011 for SBI Funds Management Pvt Ltd
 
10 Jul 2017
  UpdatesCompany UpdateDownload PDF
  Exchange Received Time  10/07/2017 11:50:29         Exchange Disseminated Time   10/07/2017 11:50:35              Time Taken   00:00:06
Sub:USFDA to Lift Import Alert 99-32 on the company's Unit-II at Visakhapatnam.

Divi's Laboratories has been informed by the US-FDA that it will lift the Import Alert 99-32 imposed on the company's Unit-II at Visakhapatnam.
We had earlier informed the Stock Exchanges that the US-FDA has issued an Import Alert under clauses 99-32 and 66-40 in March of 2017 and a warning letter in May of 2017 for our Vishakhapatnam facility. Divi's Laboratories ....
28 Jun 2017
  Outcome of Board MeetingBoard MeetingDownload PDF
  Exchange Received Time  28/06/2017 10:59:00         Exchange Disseminated Time   28/06/2017 10:59:07              Time Taken   00:00:07

Noted the completion of tenure of Mrs. S. Sridevi as an Independent Director of the company w.e.f. 22nd June, 2017 and hence she ceases to be a director of the company.
Appointed Dr. Ramesh B. V. Nimmagadda as an Additional (Independent) Director w.e.f. 27th June, 2017
Appointed Ms. Nilima Motaparti, as an Additional (Whole-time) Director w.e.f. 27th June, 2017, who was earlier appointed by the members as Chief Controller (Commercial) in the year 2012. ....
07 Jun 2017
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011Insider Trading / SASTDownload PDF
  Exchange Disseminated Time     07/06/2017 15:29:35
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Reliance Nippon Life Asset Management Ltd
 
26 May 2017
Board recommends DividendCorp. ActionDownload PDF
  Exchange Disseminated Time     26/05/2017 18:26:14
Divis Laboratories Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 26, 2017, inter alia, has recommended dividend @ 500% i.e Rs. 10/- per equity share of face value Rs. 2/- each for the year ended March 31, 2017, subject to approval of the member in ensuing Annual General Meeting (AGM). The dividend on Equity Shares, shall be paid within 30 (thirty) days from the conclusion of the AGM, the date of which will be intimated in due course.
 
  Financial Results For The Quarter And Year Ended 31St March, 2017ResultDownload PDF
  Exchange Received Time  26/05/2017 18:07:55         Exchange Disseminated Time   26/05/2017 18:08:01              Time Taken   00:00:06
Further to our letter dated 15th May, 2017, we would like to inform that the Board of Directors of the Company at its meeting held on Friday, 26th May 2017 has approved the Audited Financial Results for the quarter and year ended 31st March, 2017. Board has recommended dividend @ 500% i.e Rs. 10/- per equity share of face value Rs. 2/- each for the year ended 31st March 2017, subject to approval of the member in ensuing Annual General Meeting (AGM). ....
15 May 2017
  Board to consider FY17 Results & Dividend on May 26, 2017Corp. ActionDownload PDF
  Exchange Disseminated Time     15/05/2017 12:29:44
Divis Laboratories Ltd has informed BSE that a meeting of Board of Directors of the Company is scheduled to be held on May 26, 2017, inter alia, to consider and approve standalone and consolidated audited financial results for the year ended March 31, 2017 and to recommend dividend, if any, on Equity Shares for the financial year 2016-17.

Further, the Trading Window for dealing in securities of the Company shall remain closed for insiders ....
  Board Meeting On 05 26,2017Board MeetingDownload PDF
  Exchange Received Time  15/05/2017 12:24:06         Exchange Disseminated Time   15/05/2017 12:24:15              Time Taken   00:00:09
Notice is hereby given that a meeting of Board of Directors of the Company is scheduled to be held on Friday, the 26th day of May 2017, inter-alia, to consider and approve standalone and consolidated audited financial results for the year ended 31st March 2017 and to recommend dividend, if any, on Equity Shares for the financial year 2016-17. We further inform you that the Trading Window for dealing in securities of the Company shall remain closed ....
22 Apr 2017
  UpdatesCompany UpdateDownload PDF
  Exchange Received Time  22/04/2017 11:33:39         Exchange Disseminated Time   22/04/2017 11:33:44              Time Taken   00:00:05
Further to our earlier communication dated 8th April, 2017 to the Stock Exchanges, we wish to update that the US-FDA has issued a Warning Letter for the company's Unit-II at Visakhapatnam. Divi's Laboratories responded to the US-FDA inspection observations with an appropriate remediation process to overcome the deficiencies observed. As part of our commitments, we have also provided periodic updates to the US-FDA. In the Import Alert issued, ....
08 Apr 2017
UpdatesCompany UpdateDownload PDF
  Exchange Received Time  08/04/2017 15:00:33         Exchange Disseminated Time   08/04/2017 15:00:40              Time Taken   00:00:07
Further to our earlier communication dated 22nd March, 2017 to the Stock Exchanges, we wish to update that the US-FDA has exempted some more products manufactured at the company's Unit-II at Visakhapatnam from the Import Alert issued under clauses 66-40 & 99-32 of the FDA regulations.
 
07 Apr 2017
Compliance Certificate For Half Year Ended 31St March 2017 Company UpdateDownload PDF
  Exchange Received Time  07/04/2017 16:55:13         Exchange Disseminated Time   07/04/2017 16:55:20              Time Taken   00:00:07
Please find enclosed Compliance Certificate as required under Regulation 40(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, for the half year ended 31st March 2017
 

Disclaimer Next >>